1. Academic Validation
  2. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors

Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors

  • J Med Chem. 2011 Apr 28;54(8):2952-60. doi: 10.1021/jm200049r.
Vincent Mascitti 1 Tristan S Maurer Ralph P Robinson Jianwei Bian Carine M Boustany-Kari Thomas Brandt Benjamin M Collman Amit S Kalgutkar Michelle K Klenotic Michael T Leininger André Lowe Robert J Maguire Victoria M Masterson Zhuang Miao Emi Mukaiyama Jigna D Patel John C Pettersen Cathy Préville Brian Samas Li She Zhanna Sobol Claire M Steppan Benjamin D Stevens Benjamin A Thuma Meera Tugnait Dongxiang Zeng Tong Zhu
Affiliations

Affiliation

  • 1 Groton Laboratories, Pfizer Global Research & Development, Groton, Connecticut 06340, United States. vincent.mascitti@pfizer.com
Abstract

Compound 4 (PF-04971729) belongs to a new class of potent and selective sodium-dependent glucose cotransporter 2 inhibitors incorporating a unique dioxa-bicyclo[3.2.1]octane (bridged ketal) ring system. In this paper we present the design, synthesis, preclinical evaluation, and human dose predictions related to 4. This compound demonstrated robust urinary glucose excretion in rats and an excellent preclinical safety profile. It is currently in phase 2 clinical trials and is being evaluated for the treatment of type 2 diabetes.

Figures
Products